EUVIMEDSkopri EUVIMED
Crossref

From Pharmacophore Models to Lead Compounds: Construction and Activity Evaluation of Novel Indoleamine 2,3‐Dioxygenase‐1 Inhibitors

Shiying Zhang, Anli Zhang, Bin Sun iD

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70207 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2025. Written by Shiying Zhang and 2 co-authors. Institution: Institute of BioPharmaceutical Research, Liaocheng University, Liaocheng, People's Republic of China. Major MEDLINE topics: Indoleamine-Pyrrole 2,3,-Dioxygenase, Enzyme Inhibitors. Cited 1 times so far (Crossref); 31 references. Funded by: Natural Science Joint Foundation of Shandong Province, Natural Science Foundation of Shandong Province.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Indoleamine 2,3‐dioxygenase‐1 (IDO‐1), as a crucial immunomodulatory target, plays a pivotal role in regulating immune function. In this study, the ligand‐based pharmacophore model (HDAA) and the receptor‐based pharmacophore model (HHDA) were respectively constructed, which could comprehensively reflect the spatial distribution characteristics of the core groups of IDO‐1 inhibitors. Subsequently, these pharmacophore models were utilized to guide the design of novel IDO‐1 inhibitors through a skeleton combination approach. The corresponding molecular structures were synthesized, and evaluated for their biological activities. Notably, compound 7b exhibited highly potent IDO‐1 inhibitory activity, which contributed to the body's immune activation in vivo. In summary, the study not only constructed the rational pharmacophore and docking models but also guided the development of novel IDO‐1 inhibitor skeletons, providing a promising approach to achieving immune activation.

Subjects

MeSH terms (MEDLINE)

Indoleamine-Pyrrole 2,3,-DioxygenaseEnzyme InhibitorsMolecular Docking SimulationAnimalsHumansStructure-Activity RelationshipMiceDrug DesignLigandsPharmacophore

Author keywords

activity evaluationdrug designorganic synthesispharmacophore model

Substances

Indoleamine-Pyrrole 2,3,-DioxygenaseEnzyme InhibitorsIDO1 protein, humanLigands

Authors and institutions

  • Institute of BioPharmaceutical Research, Liaocheng University, Liaocheng, People's Republic of China.

ORCID profiles: Bin Sun

Funding

  • Natural Science Joint Foundation of Shandong Province
  • Natural Science Foundation of Shandong Province

Cite

APA

Zhang, S., Zhang, A., & Sun, B. (2025). From Pharmacophore Models to Lead Compounds: Construction and Activity Evaluation of Novel Indoleamine 2,3‐Dioxygenase‐1 Inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70207

Vancouver

Zhang S, Zhang A, Sun B. From Pharmacophore Models to Lead Compounds: Construction and Activity Evaluation of Novel Indoleamine 2,3‐Dioxygenase‐1 Inhibitors. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70207

BibTeX
@article{Zhang2025,
  author = {Zhang, Shiying and Zhang, Anli and Sun, Bin},
  title = {From Pharmacophore Models to Lead Compounds: Construction and Activity Evaluation of Novel Indoleamine 2,3‐Dioxygenase‐1 Inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70207}
}
Start for free →